Cingulate Inc Added to Broad Russell 3000E Index
I'm LongbridgeAI, I can summarize articles.Cingulate Inc (CING) was added to the Broad Russell 3000E Index on July 2, 2026. This inclusion is expected to enhance market visibility and bolster its standing in capital markets as it develops PTR-based therapies for ADHD and anxiety disorders. Additionally, the company amended an executive employment agreement extending a trial period. Analyst ratings remain mixed, with some Buy recommendations but AI analysis citing weak financial performance.
Cingulate Inc ( (CING) ) has issued an announcement.
On June 30, 2026, Cingulate’s subsidiary Cingulate Therapeutics LLC amended the employment agreement of Executive Vice President and Chief Medical Officer Matthew N. Brams, extending his full‑time trial employment period to September 30, 2026. The change clarifies the executive’s evaluation window as the company advances its clinical programs and operational strategy.
On July 2, 2026, Cingulate announced that it had been added to the Russell 3000E Index, which tracks approximately 4,000 of the largest investable U.S. equities and is widely used as a benchmark by institutional investors. Inclusion in the index is expected to enhance the company’s market visibility and could bolster its standing in the capital markets as it continues developing its PTR‑based ADHD and anxiety disorder therapies.
The most recent analyst rating on (CING) stock is a Buy
with a $52.00 price target.
To see the full list of analyst forecasts on Cingulate Inc stock,
see the CING Stock Forecast page.
Spark’s Take on CING Stock
According to Spark, TipRanks’ AI Analyst, CING is a Neutral.
The score is primarily weighed down by weak financial performance (no revenue, ongoing losses, cash burn, and leverage/financing risk). Technicals are neutral-to-mixed and do not provide strong momentum support. Corporate events are balanced—patent strength and financing flexibility are offset by the FDA delay and dilution risk—while valuation is constrained by negative earnings and no dividend.
To see Spark’s full report on CING stock,
click here.
More about Cingulate Inc
Cingulate Inc. is a Kansas City‑based biopharmaceutical company that uses its proprietary Precision Timed Release (PTR) drug delivery platform, including the Oralogik erosion barrier layer technology licensed from BDD Pharma, to develop next‑generation therapies for conditions with burdensome daily dosing. Its lead clinical program is CTx‑1301, a once‑daily dexmethylphenidate tablet for attention‑deficit/hyperactivity disorder (ADHD), with additional pipeline focus on anxiety disorders and other indications requiring multiple precisely timed doses.
The company operates in the large and growing U.S. ADHD market, which comprises roughly 100 million annual prescriptions and more than 20 million diagnosed patients, including a rapidly expanding adult segment. By targeting improved symptom control over the full active day and reducing dosing complexity, Cingulate aims to differentiate its products within the competitive neuropsychiatric therapeutics space and strengthen its positioning among institutional investors through greater market visibility.
Average Trading Volume: 562,298
Technical Sentiment Signal: Buy
Current Market Cap: $79.33M